• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[局部浸润性直肠肿瘤的定义、分类及综合治疗]

[Definition, classification and combined treatment of locally invasive rectal neoplasms].

作者信息

Knysh V I, Kim F P, Goldobenko G V, Tsariuk V F, Barsukov Iu A

出版信息

Khirurgiia (Mosk). 1994 Oct(10):20-3.

PMID:7723258
Abstract

From analysis of 490 case records of patients with stage IV A rectal carcinoma, 3 groups of patients were distinguished according to the size of the tumor and the degree of its fixation to the surrounding tissues and growth into the adjacent organs. Such locally spread tumors of the rectum must be subjected to combined treatment: preoperative large-fractional radiotherapy in concurrent local SHF-hyperthermia followed by operation 24-48 hours later. If resectability of the tumor is doubtful, a relieving colostoma is formed in the first stage and distance gammatherapy is applied in a dose of 4 Gy twice a week to a total dose of 32 Gy auring medication with metronidazole and local SHF-therapy. Concurrent intraarterial chemotherapy with 5-fluorouracil (15 mg/kg body weight) has been lately introduced into practice in the treatment of such patients. The results of this complex treatment are evaluated 3-4 weeks after the course is completed.

摘要

通过对490例IV A期直肠癌患者的病例记录进行分析,根据肿瘤大小、肿瘤与周围组织的固定程度以及向邻近器官的生长情况,区分出3组患者。这种直肠局部扩散肿瘤必须接受综合治疗:术前进行大分割放疗并同时进行局部射频热疗,然后在24至48小时后进行手术。如果肿瘤的可切除性存疑,则在第一阶段形成缓解性结肠造口术,并在服用甲硝唑和进行局部射频热疗的同时,每周两次给予4 Gy的远距离伽马射线治疗,总剂量为32 Gy。最近,在这类患者的治疗中开始采用5-氟尿嘧啶(15 mg/kg体重)进行同步动脉内化疗。在疗程结束3至4周后评估这种综合治疗的效果。

相似文献

1
[Definition, classification and combined treatment of locally invasive rectal neoplasms].[局部浸润性直肠肿瘤的定义、分类及综合治疗]
Khirurgiia (Mosk). 1994 Oct(10):20-3.
2
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.术前超分割放化疗用于既往盆腔放疗后的局部复发性直肠癌患者:一项多中心II期研究。
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18.
3
Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.治疗后TNM分期是术前化疗和放疗后固定或浸润性直肠癌生存和复发的预后指标。
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):665-77. doi: 10.1016/j.ijrobp.2004.06.206.
4
Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.局部晚期直肠癌的术前放化疗及全直肠系膜切除术:与直肠癌退缩分级的相关性
Dis Colon Rectum. 2004 Dec;47(12):2025-31. doi: 10.1007/s10350-004-0713-x.
5
[T4 rectal carcinoma. Surgical and multimodal therapy].[直肠T4期癌。手术及多模式治疗]
Chirurg. 2002 Feb;73(2):147-53. doi: 10.1007/s00104-001-0373-5.
6
Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.局部晚期直肠癌术前放化疗后的最佳手术时间
Ann Surg. 2008 Aug;248(2):243-51. doi: 10.1097/SLA.0b013e31817fc2a0.
7
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.长期术前放化疗治疗的直肠癌患者中淋巴结转移和肿瘤退缩分级的预后价值
Colorectal Dis. 2009 Mar;11(3):264-9. doi: 10.1111/j.1463-1318.2008.01599.x. Epub 2008 Jun 20.
8
[Local recurrence and survival rate after rectal cancer operations and multimodal therapy].[直肠癌手术及多模式治疗后的局部复发率和生存率]
Chirurg. 2002 Mar;73(3):245-54. doi: 10.1007/s00104-002-0428-2.
9
Preoperative chemotherapy and radiotherapy for locally advanced rectal cancer.局部晚期直肠癌的术前化疗与放疗
ANZ J Surg. 2005 May;75(5):286-91. doi: 10.1111/j.1445-2197.2005.03348.x.
10
Preoperative chemoradiotherapy in patients with locally advanced rectal cancer.局部晚期直肠癌患者的术前放化疗
Hepatogastroenterology. 2005 Jul-Aug;52(64):1095-100.